Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Protective Efficacy of Rabies Antibody After Standardized Management in High-Risk Exposure Population
ChiCTR2600124587Phase 4Not yet recruiting
- Sponsor
- Hangzhou Third People's Hospital
- Start
- May 2026
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of siravimab, Mazorelvimab and Rabies vaccine in rabies, sponsored by Hangzhou Third People's Hospital. Primary endpoints: Rabies neutralizing antibody (RVNA) level at Day 7 and Adverse reactions to Zamerovimab + Mazorelvimab injection. Planned start May 2026; status: not yet recruiting.
02
Drugs
siravimabMazorelvimabRabies vaccine
03
Conditions
rabies
Beyond the preview
Go deeper on ChiCTR2600124587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124587.